Drawing for EPIGENESIS PHARMACEUTICALS

USPTO serial 78355970

EPIGENESIS PHARMACEUTICALS

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
BELLO, ZACK
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with EPIGENESIS PHARMACEUTICALS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Albert P. Halluin

Albert P. Halluin WILSON SONSINI GOODRICH & ROSATI650 PAGE MILL ROADPALO ALTO, CA 94304-1050UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Medical diagnostic and therapeutic preparations, all for administration via diverse routes of administration including through the respiratory airways, and, medical devices for administering the pharmaceuticals, sold filled, the preparations including nucleotides, proteins and organic molecules for medical use, including macromolecules such as anti-sense oligonucleotides and enzymes and small and inorganic molecules for treatment of human and non-human animal respiratory, central nervous system, neoplastic, endocrine, immune and cardiovascular ailments, including bronchoconstriction, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, which in some cases are adenosine receptor associated symptoms; pharmaceutical preparations for testing, and preventing and therapeutically treating respiratory, airway and pulmonary diseases and conditions, such as asthma, pulmonary vasconconstriction, inflammation, allergies, impeded respiration, acute respiratory disease syndrome (ARDS), renal damage and failure, ischemia resulting from the administration of certain drugs, including adenosine and other drugs for, for example, treating supra ventricular tachycardia (SVT), adenosine stress tests, infantile respiratory distress syndrome (infantile RDS), pain, cystic fibrosis, allergic rhinitis, allergic bronchitis, pulmonary hypertension, pulmonary vasconcontriction, emphysema, chronic obstructive pulmonary disease (COPD), as well as cancers including leukemias, lymphomas, carcinomas, and the like, eg colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, etc, as well as metastatic cancers, eg, cancers which metastasized to the lung(s), breast, liver and prostateACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Oct 27, 2008MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Oct 27, 2008ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Apr 4, 2008EX5GSOU EXTENSION 5 GRANTED—
Mar 14, 2008EXT5SOU EXTENSION 5 FILED—
Mar 14, 2008EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 26, 2007EX4GSOU EXTENSION 4 GRANTED—
Sep 13, 2007EXT4SOU EXTENSION 4 FILED—
Sep 13, 2007EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 28, 2007EX3GSOU EXTENSION 3 GRANTED—
Mar 20, 2007EXT3SOU EXTENSION 3 FILED—
Mar 20, 2007EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 24, 2006EX2GSOU EXTENSION 2 GRANTED—
Sep 22, 2006EXT2SOU EXTENSION 2 FILED—
Sep 22, 2006EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 28, 2006EX1GSOU EXTENSION 1 GRANTED—
Mar 24, 2006EXT1SOU EXTENSION 1 FILED—
Mar 24, 2006EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 27, 2005NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jul 5, 2005PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 15, 2005NPUBNOTICE OF PUBLICATION—
Mar 28, 2005PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Mar 25, 2005ALIEASSIGNED TO LIE—
Mar 18, 2005CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 17, 2005ACECAMENDMENT FROM APPLICANT ENTERED—
Jan 31, 2005CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 31, 2005MAILPAPER RECEIVED—
Oct 5, 2004TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Aug 21, 2004GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 12, 2004DOCKASSIGNED TO EXAMINER—
Jul 20, 2004PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Jul 16, 2004MAILPAPER RECEIVED—
Feb 2, 2004NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance